{"name":"TUMOR","title":"","children":[{"id":"breast","name":"breast","presenterLast":"breast","children":[{"id":875,"name":"breast_875","title":"Small-molecule inhibition of cathepsins L and K as potential therapeutics for macrophage-driven breast cancer","presenterFirst":"Samantha","presenterLast":"Dykes","keywords":"Breast cancer;Macrophages;Cathepsin L;Invasion","target":"Cathepsin","tumor":"breast","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":2853,"name":"breast_2853","title":"Therapy-induced senescence associated secretory phenotype enhances breast cancer cell invasion and stemness via CXCR1/2-CXCR1/2 ligands axis","presenterFirst":"Yong Won","presenterLast":"Choi","keywords":"Senescence;Interleukin-8;Breast cancer","target":"CXCR1/2","tumor":"breast","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":3135,"name":"breast_3135","title":"Novel nano-molar small-molecule STAT3 inhibitor series with antitumor activities against human breast cancer","presenterFirst":"Peibin","presenterLast":"Yue","keywords":"STAT3;Small molecule inhibitor;Breast cancer;Antitumor agents","target":"SATA3","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":3522,"name":"breast_3522","title":"Preclinical antitumor activity of a CC chemokine receptor (CCR) 2/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade","presenterFirst":"Qihong","presenterLast":"Zhao","keywords":"Chemokine receptor;Immunosuppression;CCR2/5;Tumor-associated myeloid and T cells","target":"CCR2/5","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3537,"name":"breast_3537","title":"Interference of PD-1 and PD-L1 interaction with small-molecule inhibitors enhances the efficacy of tumor-specific CTLs","presenterFirst":"Priscilla","presenterLast":"Redd","keywords":"Cytotoxic T lymphocytes;Small molecule inhibitor;Immunotherapy;PD-L1","target":"PD1/L1","tumor":"breast","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3790,"name":"breast_3790","title":"Dual inhibitor of immunokinase and pan-RAF for the treatment of KRAS-mutated cancers","presenterFirst":"Sungpyo","presenterLast":"Hong","keywords":"Immunotherapy;M-CSF;Macrophages;RAF kinase","target":"CSF1-R","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":4571,"name":"breast_4571","title":"EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models","presenterFirst":"Barbara","presenterLast":"Volz","keywords":"Immunomodulation;Tumor microenvironment;T cell","target":"TLR9","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5135,"name":"breast_5135","title":"Targeting CX3CR1 Impairs the reseeding and colonization of circulating tumor cells and decelerates metastatic progression","presenterFirst":"Chen","presenterLast":"Qian","keywords":"Circulating tumor cells;Metastasis;Combination therapy","target":"CX3CR1","tumor":"breast","sage":"discovery","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":5324,"name":"breast_5324","title":"Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation and function of suppressive myeloid cells","presenterFirst":"Min-Hee","presenterLast":"Oh","keywords":"Tumor microenvironment;Innate immunity;Metastatic tumors;Metabolism","target":"glutamine","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":6224,"name":"breast_6224","title":"The role of MEN1611, a class I PI3-kinases (PI3Ks) inhibitor, in reprogramming the pro-tumoral inflammatory environment","presenterFirst":"Stefania","presenterLast":"Capano","keywords":"PI3K;Macrophages","target":"PI3Kg","tumor":"breast","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6327,"name":"breast_6327","title":"Endogenous STING inhibition induces breast cancer cell death","presenterFirst":"Hery","presenterLast":"Ratsima","keywords":"Breast cancer;Drug resistance;DNA damage;Immunotherapy","target":"STING","tumor":"breast","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6720,"name":"breast_6720","title":"Targeting HDAC6 to reduce the aggressiveness of metastatic breast cancer in immunotherapy","presenterFirst":"Debarati","presenterLast":"Banik","keywords":"Metastasis;Invasion;Checkpoint;Microenvironment","target":"HDAC6","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":10832,"name":"breast_10832","title":"The aryl hydrocarbon receptor as driver of cancer immunity","presenterFirst":"David","presenterLast":"Sherr","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Oral Cancer;Cancer immunotherapy","target":"AHR","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":10999,"name":"breast_10999","title":"Nanoparticle-incorporated STING activator as an immunotherapeutic for PD-L1 resistant triple-negative breast cancer","presenterFirst":"Ning","presenterLast":"Cheng","keywords":"Macrophages;STING agonist;Nanoparticle;Immunotherapy","target":"STING","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"}]},{"id":"colorectal","name":"colorectal","presenterLast":"colorectal","children":[{"id":2082,"name":"colorectal_2082","title":"Novel small-molecule inhibitor of PD1/PDL1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy","presenterFirst":"Yuguang","presenterLast":"Wang","keywords":"Immunotherapy;Small molecule PD1/PDL1 inhibitor;anti-CTLA4;Epacadostat","target":"PD1/L1","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2186,"name":"colorectal_2186","title":"High-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of CTL antigen-specific tumor cell killing","presenterFirst":"Patrick","presenterLast":"Lizotte","keywords":"Epidermal growth factor receptor;Antigen presentation;Immunotherapy;CRISPR/Cas9","target":"EGFR","tumor":"colorectal","sage":"discovery","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":2290,"name":"colorectal_2290","title":"Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody","presenterFirst":"Yosuke","presenterLast":"Ota","keywords":"Combination therapy;TLR7;PD-1;memory T cell","target":"TLR7","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2320,"name":"colorectal_2320","title":"Depletion of blood arginine with pegzilarginase (AEB1102) in combination with anti-PD-L1 increases tumor infiltration by immune cells and enhances antitumor activity","presenterFirst":"Giulia","presenterLast":"Agnello","keywords":"Arginine deprivation;Tumor microenvironment;Metabolism;Checkpoint inhibitors","target":"arginase1","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2544,"name":"colorectal_2544","title":"TLR9 agonist SNA-induced innate and adaptive immune responses in tumor microenvironment enhance checkpoint inhibitor antitumor activity in mouse tumor models","presenterFirst":"SubbaRao","presenterLast":"Nallagatla","keywords":"Immunostimulation;Innate immunity;Checkpoint;Antitumor activity","target":"TLR9","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2562,"name":"colorectal_2562","title":"EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic","presenterFirst":"Srinivas","presenterLast":"Gullapalli","keywords":"Cancer immunotherapy;Checkpoint;Tumor microenvironment;Drug discovery","target":"IDO1_TD2","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3070,"name":"colorectal_3070","title":"Triple combination of IMO-2125, epacadostat and anti-PD-1 antibody demonstrates maximal antitumor efficacy and eradicates large established tumors in preclinical models","presenterFirst":"Daqing","presenterLast":"Wang","keywords":"Immunotherapy;Tumor microenvironment;Immunomodulation;Combination therapy","target":"TLR9","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3142,"name":"colorectal_3142","title":"Synergistic immunotherapeutic effects of TLR7/8 agonist on low-dose cyclophosphamide-treated C26 model","presenterFirst":"Lixin","presenterLast":"Li","keywords":"Immunotherapy;Cyclophosphamide;Toll like receptor ligand","target":"TLR7/8","tumor":"colorectal","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3150,"name":"colorectal_3150","title":"Small-molecule antagonists of the Aryl Hydrocarbon Receptor (AhR) promote activation of human PBMCs in vitro and demonstrate significant impact on tumor growth and immune modulation in vivo","presenterFirst":"Fred","presenterLast":"Aswad","keywords":"Aryl hydrocarbon receptor;Immunomodulation;Small molecule inhibitor;Drug discovery","target":"AHR","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":3522,"name":"colorectal_3522","title":"Preclinical antitumor activity of a CC chemokine receptor (CCR) 2/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade","presenterFirst":"Qihong","presenterLast":"Zhao","keywords":"Chemokine receptor;Immunosuppression;CCR2/5;Tumor-associated myeloid and T cells","target":"CCR2/5","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3759,"name":"colorectal_3759","title":"Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRP\u03b1 axis","presenterFirst":"Murali","presenterLast":"Ramachandra","keywords":"Immunotherapy;Small molecule drugs;Macrophages;Innate immunity","target":"CD47_SIRP","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3790,"name":"colorectal_3790","title":"Dual inhibitor of immunokinase and pan-RAF for the treatment of KRAS-mutated cancers","presenterFirst":"Sungpyo","presenterLast":"Hong","keywords":"Immunotherapy;M-CSF;Macrophages;RAF kinase","target":"CSF1-R","tumor":"colorectal","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":4151,"name":"colorectal_4151","title":"Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity","presenterFirst":"Jingsong","presenterLast":"Yang","keywords":"Cancer immunotherapy;Immunostimulation;Antigen presentation;Interferons","target":"STING","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":4503,"name":"colorectal_4503","title":"Impact of IDO inhibitor on tryptophan and kynurenine pathway reflected in the tumor microenvironment and highlighted using quantitative mass spectrometry imaging","presenterFirst":"Lauranne","presenterLast":"Poncelet","keywords":"Mass spectrometry;Mass spectrometry;Drug delivery","target":"IDO1","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":4521,"name":"colorectal_4521","title":"Myeloid-derived suppressor cells potentiate colorectal carcinogenesis: Identification of a novel RIPK3-PGE2 circuit in tumor microenvironment","presenterFirst":"Yongsheng","presenterLast":"Li","keywords":"Gastrointestinal cancers: colorectal;Prostaglandin E2;NF-[kappa]B;Cyclooxygenase","target":"PGE2","tumor":"colorectal","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":4571,"name":"colorectal_4571","title":"EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models","presenterFirst":"Barbara","presenterLast":"Volz","keywords":"Immunomodulation;Tumor microenvironment;T cell","target":"TLR9","tumor":"colorectal","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":4634,"name":"colorectal_4634","title":"Novel, first-in-class dual inhibitors of lysine specific demethylase 1 (LSD1) and histone deacetylatse 1 (HDAC) for treatment of cancer","presenterFirst":"Dhanalakshmi","presenterLast":"Sivanandhan","keywords":"Small molecule inhibitor;Epigenetics","target":"LSD1_HDAC","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5025,"name":"colorectal_5025","title":"Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors","presenterFirst":"Samanthi","presenterLast":"Perera","keywords":"Immunotherapy;Innate immunity;Adoptive immunotherapy;Mouse models","target":"STING","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5170,"name":"colorectal_5170","title":"Metabolic modulation of the tumor microenvironment using Synthetic Biotic\u2122 Medicines","presenterFirst":"Kip","presenterLast":"West","keywords":"Immunotherapy;Immunomodulation;Tumor microenvironment;Bacterial treatment","target":"KYN","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5435,"name":"colorectal_5435","title":"Mobilization of tumor-primed, marrow-infiltrating lymphocytes into peripheral blood with inhibitors of E-selectin or E-selectin and CXCR4","presenterFirst":"William","presenterLast":"Fogler","keywords":"E-selectin;CXCR4;T lymphocytes;Bone marrow","target":"Eselectin_CXCR4","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5745,"name":"colorectal_5745","title":"Preclinical evaluation of TQBWX220, a small-molecule inhibitor of IDO1","presenterFirst":"Shilan","presenterLast":"Liu","keywords":"Immunotherapy;Tumor immunity;Tumor microenvironment;IDO1 inhibitor","target":"IDO1","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6224,"name":"colorectal_6224","title":"The role of MEN1611, a class I PI3-kinases (PI3Ks) inhibitor, in reprogramming the pro-tumoral inflammatory environment","presenterFirst":"Stefania","presenterLast":"Capano","keywords":"PI3K;Macrophages","target":"PI3Kg","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6343,"name":"colorectal_6343","title":"4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for combinations with different cancer immunotherapy approaches","presenterFirst":"Svetlana","presenterLast":"Hamm","keywords":"Histone deacetylase inhibitor;Combination therapy;Checkpoint","target":"HDAC","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6589,"name":"colorectal_6589","title":"PD-L1 pathway activation as an escape mechanism of resistance to MEK inhibitor treatment in human colorectal cancer models","presenterFirst":"Stefania","presenterLast":"Napolitano","keywords":"Gastrointestinal cancers: colorectal;MEK Inhibitor;Immunomodulation","target":"MEK","tumor":"colorectal","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical in vitro"},{"id":7149,"name":"colorectal_7149","title":"High-throughput analysis of MAPK and JAK-STAT signaling in CT26 tumors using a combination of immunophenotyping and phospho-flow cytometry","presenterFirst":"Scott","presenterLast":"Wise","keywords":"Flow cytometry;Phosphorylation;Immunomodulation","target":"MEK","tumor":"colorectal","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":7423,"name":"colorectal_7423","title":"Inhibition of chemokine receptor 2 (CCR2) with a small molecule antagonist enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumors: Reducing tumor size and increasing long term survival","presenterFirst":"James","presenterLast":"Campbell","keywords":"Chemokine receptor;Colorectal cancer;Checkpoint;Gastrointestinal cancers: colorectal","target":"CCR2/5","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7608,"name":"colorectal_7608","title":"Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor","presenterFirst":"Jeremy","presenterLast":"Tchaicha","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Tumor microenvironment","target":"AHR","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":9276,"name":"colorectal_9276","title":"A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer","presenterFirst":"Dung","presenterLast":"Le","keywords":"Chemokine receptor;immunosuppression;CCR2/5;tumor-associated myeloid and T cells","target":"CCR2/5","tumor":"colorectal","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10677,"name":"colorectal_10677","title":"Discovery of an imidazopyridine series of potent human IDO1 inhibitors with robust target engagement in a preclinical tumor model","presenterFirst":"Alessia","presenterLast":"Petrocchi","keywords":"Drug discovery;IDO1 inhibitors","target":"IDO1","tumor":"colorectal","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":10771,"name":"colorectal_10771","title":"Promoting an anti-tumor immune environment with a novel, exquisitely selective CSF1R inhibitor","presenterFirst":"Joseph","presenterLast":"Marszalek","keywords":"Macrophages;Drug discovery;CSF1R","target":"CSF1-R","tumor":"colorectal","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"gastric","name":"gastric","presenterLast":"gastric","children":[{"id":7441,"name":"gastric_7441","title":"EBV associated tumors have increased regulatory T cell recruitment and are therefore a potential indication for treatment with potent and selective small molecule CCR4 antagonists","presenterFirst":"Oezcan","presenterLast":"Talay","keywords":"Epstein-Barr virus;Chemokines;Regulatory T cells","target":"CCR4","tumor":"gastric","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"hcc","name":"hcc","presenterLast":"hcc","children":[{"id":2952,"name":"hcc_2952","title":"Identifying characteristics of orthotopic HCC mouse models to predict response to immunotherapy","presenterFirst":"Carina","presenterLast":"Hage","keywords":"Hepatocellular carcinoma;Immunotherapy;Mouse models;Combination therapy","target":"TLR7/8","tumor":"hcc","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3197,"name":"hcc_3197","title":"The biological significance of CCL 16 regulated by thyroid hormone in liver cancer cells","presenterFirst":"Cheng-Heng","presenterLast":"Wu","keywords":"Hepatocellular carcinoma;Chemokines;Macrophages;Thyroid Hormone","target":"CCL16","tumor":"hcc","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"headneck","name":"headneck","presenterLast":"headneck","children":[{"id":3152,"name":"headneck_3152","title":"CXCR7 promotes the migration and invasion of head and neck squamous cell carcinoma through Smad2/Akt signaling","presenterFirst":"Nayoung","presenterLast":"Kim","keywords":"Chemokine receptor;CXCR7;Epithelial-to-mesenchymal transition","target":"CXCR7","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":3158,"name":"headneck_3158","title":"The combination of CXCR4 and checkpoint receptor inhibition improves survival in an orthotopic murine glioma model","presenterFirst":"Adela","presenterLast":"Wu","keywords":"CXCR4;Checkpoint;Angiogenesis;Glioma","target":"CXCR7","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":3402,"name":"headneck_3402","title":"An epigenetic and immunologic approach to optimize therapy for HNSCC","presenterFirst":"Rachel","presenterLast":"Goldberg","keywords":"Epigenetics;Immunotherapy;Head and neck cancer","target":"DNAMT","tumor":"headneck","sage":"discovery","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":5329,"name":"headneck_5329","title":"Targeting the kynurenine pathway as a novel metabolic treatment for head and neck cancer","presenterFirst":"Chitra","presenterLast":"Subramanian","keywords":"Head and neck squamous cell carcinoma;IDO1;glycolysis;Kynurenine","target":"IDO1_IDO2_TDO","tumor":"headneck","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6279,"name":"headneck_6279","title":"Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells","presenterFirst":"Nobuyuki","presenterLast":"Kuribayashi","keywords":"CXCR4;Metastasis;Oral Cancer","target":"CXCR4","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":7441,"name":"headneck_7441","title":"EBV associated tumors have increased regulatory T cell recruitment and are therefore a potential indication for treatment with potent and selective small molecule CCR4 antagonists","presenterFirst":"Oezcan","presenterLast":"Talay","keywords":"Epstein-Barr virus;Chemokines;Regulatory T cells","target":"CCR4","tumor":"headneck","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":10663,"name":"headneck_10663","title":"Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment na\u00efve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)","presenterFirst":"Abraham","presenterLast":"Leung","keywords":"Immunotherapy;Innate immunity;Checkpoint;Head and neck cancers","target":"TLR9","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10832,"name":"headneck_10832","title":"The aryl hydrocarbon receptor as driver of cancer immunity","presenterFirst":"David","presenterLast":"Sherr","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Oral Cancer;Cancer immunotherapy","target":"AHR","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"leukemia","name":"leukemia","presenterLast":"leukemia","children":[{"id":3285,"name":"leukemia_3285","title":"Preclinical study of a novel TLR8 selective agonist for cancer immunotherapy","presenterFirst":"Yuxun","presenterLast":"Wang","keywords":"Cancer immunotherapy;Targeted therapy;Innate immunity;Drug discovery","target":"TLR8","tumor":"leukemia","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":4840,"name":"leukemia_4840","title":"Transcriptomics analysis of SNX-2112 on immune and mitochodrial genes","presenterFirst":"Everardus","presenterLast":"Orlemans","keywords":"Immune response;SNX-2112;epigenetic Hsp90 inhibitor;oncometabolism","target":"HSP90","tumor":"leukemia","sage":"discovery","pharma":"pharma","combo":"no","model":"in silico"}]},{"id":"lung","name":"lung","presenterLast":"lung","children":[{"id":455,"name":"lung_455","title":"Traf2-and Nck-interacting kinase (TNIK) inhibitor, NCB-0846, suppresses TGF-\u03b21-induced epithelial-mesenchymal transition in lung cancer","presenterFirst":"Teppei","presenterLast":"Sugano","keywords":"EMT;TGF-beta;Metastasis;Therapeutics","target":"TNIK","tumor":"lung","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":609,"name":"lung_609","title":"Targeting kynurenine pathway for the treatment of cisplatin-resistant lung cancer","presenterFirst":"Medhi","presenterLast":"Wangpaichitr","keywords":"Lung cancer;Cisplatin resistance;Metabolism","target":"IDO1_KYN","tumor":"lung","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":881,"name":"lung_881","title":"Protumoral and pro-metastatic effects of TLR7 in lung cancer","presenterFirst":"Isabelle","presenterLast":"Cremer","keywords":"Tumor microenvironment;TLR7;pro-tumoral;resistance to chemotherapy","target":"TLR7","tumor":"lung","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":6914,"name":"lung_6914","title":"Suppression of myeloid cell arginase activity leads to therapeutic response in Kras mutant lung cancer by activating anti-tumor immunity","presenterFirst":"Juan","presenterLast":"Miret","keywords":"Arginine deprivation;Immune response","target":"arginase1","tumor":"lung","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"}]},{"id":"lymphoma","name":"lymphoma","presenterLast":"lymphoma","children":[{"id":2090,"name":"lymphoma_2090","title":"Glycogen synthase kinase (GSK-3) inactivation downregulates PD-1 and synergizes with PD-1/PL1 and CTLA-4 blockade in cancer immunotherapy","presenterFirst":"Christopher","presenterLast":"Rudd","keywords":"T cell;Cancer immunotherapy;Combination therapy;melanoma","target":"GSK-3","tumor":"lymphoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":2544,"name":"lymphoma_2544","title":"TLR9 agonist SNA-induced innate and adaptive immune responses in tumor microenvironment enhance checkpoint inhibitor antitumor activity in mouse tumor models","presenterFirst":"SubbaRao","presenterLast":"Nallagatla","keywords":"Immunostimulation;Innate immunity;Checkpoint;Antitumor activity","target":"TLR9","tumor":"lymphoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3759,"name":"lymphoma_3759","title":"Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRP\u03b1 axis","presenterFirst":"Murali","presenterLast":"Ramachandra","keywords":"Immunotherapy;Small molecule drugs;Macrophages;Innate immunity","target":"CD47_SIRP","tumor":"lymphoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":4571,"name":"lymphoma_4571","title":"EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models","presenterFirst":"Barbara","presenterLast":"Volz","keywords":"Immunomodulation;Tumor microenvironment;T cell","target":"TLR9","tumor":"lymphoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":7441,"name":"lymphoma_7441","title":"EBV associated tumors have increased regulatory T cell recruitment and are therefore a potential indication for treatment with potent and selective small molecule CCR4 antagonists","presenterFirst":"Oezcan","presenterLast":"Talay","keywords":"Epstein-Barr virus;Chemokines;Regulatory T cells","target":"CCR4","tumor":"lymphoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"melanoma","name":"melanoma","presenterLast":"melanoma","children":[{"id":2090,"name":"melanoma_2090","title":"Glycogen synthase kinase (GSK-3) inactivation downregulates PD-1 and synergizes with PD-1/PL1 and CTLA-4 blockade in cancer immunotherapy","presenterFirst":"Christopher","presenterLast":"Rudd","keywords":"T cell;Cancer immunotherapy;Combination therapy;melanoma","target":"GSK-3","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":2562,"name":"melanoma_2562","title":"EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic","presenterFirst":"Srinivas","presenterLast":"Gullapalli","keywords":"Cancer immunotherapy;Checkpoint;Tumor microenvironment;Drug discovery","target":"IDO1_TD2","tumor":"melanoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":2758,"name":"melanoma_2758","title":"Targeting autophagy inhibits B16-F10 melanoma growth by enhancing the infiltration of functional NK cells in a CCL5-dependent manner","presenterFirst":"Bassam","presenterLast":"Janji","keywords":"Autophagy;Chemokines;melanoma;Natural killer cells","target":"CCL5","tumor":"melanoma","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":4571,"name":"melanoma_4571","title":"EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models","presenterFirst":"Barbara","presenterLast":"Volz","keywords":"Immunomodulation;Tumor microenvironment;T cell","target":"TLR9","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":4840,"name":"melanoma_4840","title":"Transcriptomics analysis of SNX-2112 on immune and mitochodrial genes","presenterFirst":"Everardus","presenterLast":"Orlemans","keywords":"Immune response;SNX-2112;epigenetic Hsp90 inhibitor;oncometabolism","target":"HSP90","tumor":"melanoma","sage":"discovery","pharma":"pharma","combo":"no","model":"in silico"},{"id":5025,"name":"melanoma_5025","title":"Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors","presenterFirst":"Samanthi","presenterLast":"Perera","keywords":"Immunotherapy;Innate immunity;Adoptive immunotherapy;Mouse models","target":"STING","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5311,"name":"melanoma_5311","title":"CXCR4 inhibition modulates tumor microenvironment and robustly inhibits growth of B16-OVA melanoma","presenterFirst":"James","presenterLast":"Mier","keywords":"CXCR4;T cell;melanoma","target":"CXCR4","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5631,"name":"melanoma_5631","title":"X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma","presenterFirst":"Robert","presenterLast":"Andtbacka","keywords":"melanoma;Tumor microenvironment;CXCR4;Immunotherapy","target":"CXCR4","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":6137,"name":"melanoma_6137","title":"Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies","presenterFirst":"Katharina","presenterLast":"Deschler","keywords":"Innate immunity;Checkpoint;T lymphocytes","target":"TLR7/8","tumor":"melanoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6604,"name":"melanoma_6604","title":"Targeting PKR-like endoplasmic reticulum kinase modulates metabolism to promote T-cell effector function and PD1 immunotherapy responsiveness","presenterFirst":"Katherine","presenterLast":"Cook","keywords":"T cell;Metabolism;Immunotherapy;Stress response","target":"PERK","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":6720,"name":"melanoma_6720","title":"Targeting HDAC6 to reduce the aggressiveness of metastatic breast cancer in immunotherapy","presenterFirst":"Debarati","presenterLast":"Banik","keywords":"Metastasis;Invasion;Checkpoint;Microenvironment","target":"HDAC6","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":7521,"name":"melanoma_7521","title":"Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing","presenterFirst":"Kathryn","presenterLast":"Fraser","keywords":"Natural killer cells;Immunotherapy;Antibody","target":"PAMP","tumor":"melanoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7608,"name":"melanoma_7608","title":"Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor","presenterFirst":"Jeremy","presenterLast":"Tchaicha","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Tumor microenvironment","target":"AHR","tumor":"melanoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7958,"name":"melanoma_7958","title":"A highly potent novel class of SRC-3 inhibitors for the treatment of uveal melanoma","presenterFirst":"Salma","presenterLast":"Kaochar","keywords":"Melanoma/skin cancers;Uveal Melanoma;SRC-3;GNAQ mutant","target":"p160SRC","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":8050,"name":"melanoma_8050","title":"The HDAC6 inhibitor Nexturastat A improves<i> in vivo</i> PD-1 immune blockade","presenterFirst":"Alejandro","presenterLast":"Villagra","keywords":"melanoma;Histone deacetylase inhibitor;Immunotherapy","target":"HDC6","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":10610,"name":"melanoma_10610","title":"Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma","presenterFirst":"Mohammed","presenterLast":"Milhem","keywords":"CpG oligodeoxynucleotides;CMP-001;TLR9 agonist;PD-1 Resistant","target":"TLR9","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10731,"name":"melanoma_10731","title":"Durability of responses to the combination of SD-101 and pembrolizumab in advanced metastatic melanoma: Results of a phase Ib, multicenter study","presenterFirst":"Robert","presenterLast":"Janssen","keywords":"CpG oligodeoxynucleotides;anti-PD-1 therapy;Immunotherapy;SD-101","target":"TLR9","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10832,"name":"melanoma_10832","title":"The aryl hydrocarbon receptor as driver of cancer immunity","presenterFirst":"David","presenterLast":"Sherr","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Oral Cancer;Cancer immunotherapy","target":"AHR","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":10861,"name":"melanoma_10861","title":"Imprime PGG, a soluble yeast \u03b2-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients","presenterFirst":"Mark","presenterLast":"Uhlik","keywords":"Immune response;Imprime PGG;melanoma;Triple negative breast cancer","target":"PAMP","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"clinical"}]},{"id":"multiple","name":"multiple","presenterLast":"multiple","children":[{"id":6119,"name":"multiple_6119","title":"NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders","presenterFirst":"Izhak","presenterLast":"Haviv","keywords":"Drug resistance;Immunomodulation;Combination therapy;Efficacy","target":"STAT3_IRS1/2","tumor":"multiple","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":8992,"name":"multiple_8992","title":"Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study","presenterFirst":"Aung","presenterLast":"Naing","keywords":"Immunotherapy;Pancreatic cancer;Combination therapy;Phase 1","target":"IDO1","tumor":"multiple","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10805,"name":"multiple_10805","title":"Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors","presenterFirst":"Humberto","presenterLast":"Lara-Guerra","keywords":"Arginine deprivation;Solid tumors;pegzilarginase","target":"arginase1","tumor":"multiple","sage":"target-tumor","pharma":"academia","combo":"no","model":"clinical"}]},{"id":"NA","name":"NA","presenterLast":"NA","children":[{"id":2017,"name":"NA_2017","title":"Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers","presenterFirst":"Shoujun","presenterLast":"Chen","keywords":"Immunotherapy;IDO1 inhibitor;Immuno-oncology;PD-1 inhibitor","target":"IDO1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":2629,"name":"NA_2629","title":"Monitoring CD73 and CD39 ectonucleotidase activities and their modulation by antibodies and small molecules inhibitors","presenterFirst":"Said","presenterLast":"Goueli","keywords":"Cancer marker;Signaling pathways;Hypoxia-inducible genes;Small molecule inhibitor","target":"CD39_CD73","tumor":"NA","sage":"discovery","pharma":"academia","combo":"no","model":"in silico"},{"id":2858,"name":"NA_2858","title":"High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models","presenterFirst":"Charles","presenterLast":"Sinclair","keywords":"Regulatory T cells;Foxp3;Antisense oligonucleotides","target":"Foxp3","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":2933,"name":"NA_2933","title":"HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition","presenterFirst":"Jie","presenterLast":"Chen","keywords":"Histone deacetylase;MDSCs;C/EBPbeta","target":"HDAC11","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":2992,"name":"NA_2992","title":"Rational design of small-molecule immune checkpoints' inhibitors","presenterFirst":"Khaled","presenterLast":"Barakat","keywords":"Cancer;Immunomodulation;Cancer immunotherapy;Immune response","target":"PD1/L1","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"NA"},{"id":3077,"name":"NA_3077","title":"NKTR-262: Prodrug pharmacokinetics in mice, rats, and dogs","presenterFirst":"Myong","presenterLast":"Lee","keywords":"Immunotherapy","target":"TLR7/8","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":3556,"name":"NA_3556","title":"Discovery and optimization of potent and selective inhibitors of USP7 to enhance anti-tumor immunity and target tumor growth","presenterFirst":"Paul","presenterLast":"Kassner","keywords":"Tumor immunity;Regulatory T cell;Deubiquitinase inhibitor;p53","target":"USP7","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical in vitro"},{"id":3732,"name":"NA_3732","title":"NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML","presenterFirst":"Marina","presenterLast":"Ciomei","keywords":"Leukemias: acute myeloid;FLT3;CSF-1R;NMS-P088","target":"CSF1-R","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":3846,"name":"NA_3846","title":"Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models","presenterFirst":"Yifan","presenterLast":"Zhai","keywords":"IAP;Checkpoint;Immunotherapy","target":"IAP","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":5151,"name":"NA_5151","title":"Targeting glutamine metabolism as a means of enhancing antitumor T-cell responses","presenterFirst":"Robert","presenterLast":"Leone","keywords":"Immunotherapy;Metabolism;Checkpoint;Glutamine","target":"glutamine","tumor":"NA","sage":"discovery","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":5335,"name":"NA_5335","title":"Indoximod modulates AhR-driven transcription of genes that control immune function","presenterFirst":"Erik","presenterLast":"Brincks","keywords":"Immunotherapy;Aryl hydrocarbon receptor;Immunomodulation","target":"IDO1_IDO2","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5395,"name":"NA_5395","title":"Kit-dependent tissue resident macrophage progenitors drive cancer progression","presenterFirst":"Paulina","presenterLast":"Pathria","keywords":"Macrophages;Inflammation;Kit tyrosine kinase;Stem cells","target":"KIT_SCF","tumor":"NA","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5676,"name":"NA_5676","title":"eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, regulates T-cell differentiation promoting an antitumor immune response","presenterFirst":"Rajesh","presenterLast":"Sharma","keywords":"Immunotherapy;MNK1/2;T cell differentiation;Antitumor activity","target":"MNK1/2","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5685,"name":"NA_5685","title":"Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response","presenterFirst":"Craig","presenterLast":"Stumpf","keywords":"Immunomodulation;T cell;MNK;eFT508","target":"MNK1/2","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6200,"name":"NA_6200","title":"High-throughput fluorescence-based assay for screening of Arginase I inhibitors for cancer immunotherapy","presenterFirst":"Yvonne","presenterLast":"Grobben","keywords":"Immunotherapy;Structure-based drug design;High throughput assay;Arginase","target":"arginase1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":6433,"name":"NA_6433","title":"Identification and characterization of the IDO1 inhibitor LY3381916","presenterFirst":"Frank","presenterLast":"Dorsey","keywords":"Immunomodulation;Small molecule inhibitor;Immunotherapy;Lung cancer","target":"IDO1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6738,"name":"NA_6738","title":"Identification and optimization of chemical compounds as potent agonists of human STING with anticancer activity in mice","presenterFirst":"Jian Hui","presenterLast":"Wu","keywords":"Small molecule drugs;STING Agonist;Prostate cancer","target":"STING","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6912,"name":"NA_6912","title":"Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214","presenterFirst":"Saul","presenterLast":"Kivimae","keywords":"Dendritic cells;Tumor immunity;Cancer immunotherapy;T cell","target":"TLR7/8","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7006,"name":"NA_7006","title":"Small synthetic, multivalent bicyclic peptides that activate T cell costimulatory protein CD137","presenterFirst":"Peter","presenterLast":"Park","keywords":"Immunotherapy;Co-stimulation;Cancer therapy;Targeted therapy","target":"CD137","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":7410,"name":"NA_7410","title":"Mechanistic and pharmacodynamic characterization of the immuno-oncological activity of RXDX-106, a novel TYRO3, AXL, and MER (TAM) inhibitor in clinical development","presenterFirst":"Amanda","presenterLast":"Albert","keywords":"Immunomodulation;Innate immunity;Tyrosine kinase inhibitor;Macrophages","target":"TAM","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":7442,"name":"NA_7442","title":"Targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine","presenterFirst":"Xiaoyan","presenterLast":"Zhang","keywords":"Immunotherapy;Tumor microenvironment","target":"KYN","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7627,"name":"NA_7627","title":"The rational design and evaluation of a peptide inhibitor of the PD-1/PD-L1 interaction","presenterFirst":"Rebecca","presenterLast":"Boohaker","keywords":"Immunomodulation;T cell;T lymphocytes;Drug design","target":"PD1/L1","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":8167,"name":"NA_8167","title":"Discovery of ENPP1 inhibitors as agonists of STING pathway","presenterFirst":"Sunil","presenterLast":"Sharma","keywords":"Immunomodulation;Therapeutics;Small molecule inhibitor;Cancer immunotherapy","target":"ENPP1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":8244,"name":"NA_8244","title":"Intratumoral activation of STING with a synthetic cyclic dinucleotide elicits antitumor CD8 T-cell immunity that effectively combines with checkpoint inhibitors","presenterFirst":"Sarah","presenterLast":"McWhirter","keywords":"Checkpoint;Cancer immunotherapy;Innate immunity;Tumor microenvironment","target":"STING","tumor":"NA","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":8314,"name":"NA_8314","title":"T-cell activation through the inhibition of tumor-expressed IDO1 activity in tryptophan metabolism pathway","presenterFirst":"Frank","presenterLast":"Xing","keywords":"T cell;IDO1","target":"IDO1","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":9307,"name":"NA_9307","title":"The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model","presenterFirst":"Wen-Hai","presenterLast":"Huang","keywords":"Drug discovery;Pharmacophore;CXCR2;antagonists","target":"CXCR2","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"in silico"}]},{"id":"ovarian","name":"ovarian","presenterLast":"ovarian","children":[{"id":1982,"name":"ovarian_1982","title":"Tryptophan catabolism in ovarian cancer","presenterFirst":"Lynelle","presenterLast":"Smith","keywords":"Gynecological cancers: ovarian;Ovarian cancer - serous;Tumor immunity;Immunomodulation","target":"TDO2","tumor":"ovarian","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":2325,"name":"ovarian_2325","title":"Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models","presenterFirst":"Sarah","presenterLast":"Wang","keywords":"Combination studies;Checkpoint;PARP;Combination therapy","target":"PARP1/2","tumor":"ovarian","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7220,"name":"ovarian_7220","title":"Reprogramming of tumor-associated macrophages by a short synthetic peptide eradicates ovarian cancer","presenterFirst":"Reshma","presenterLast":"Bhowmick","keywords":"Macrophages;Gynecological cancers: ovarian;Microenvironment;Innate immunity","target":"PEDF","tumor":"ovarian","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":7250,"name":"ovarian_7250","title":"MPL-5821, a macrophage targeted ESM<sup>TM</sup> p38 MAPK inhibitor, inhibits the production of TLR agonist induced IL-10 whilst sparing T-cell functionality","presenterFirst":"David","presenterLast":"Moffat","keywords":"Macrophages;MAP kinase;Immune response;Interleukin-10","target":"MAPK_TLR","tumor":"ovarian","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":8151,"name":"ovarian_8151","title":"The PARP inhibitor rucaparib activates the STING pathway and enhances antitumor responses of immune checkpoint inhibitors in <i>BRCA</i> deficient syngeneic models","presenterFirst":"Andrew","presenterLast":"Simmons","keywords":"PARP;BRCA;Immune response;Checkpoint","target":"PARP1/2","tumor":"ovarian","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"}]},{"id":"pancreatic","name":"pancreatic","presenterLast":"pancreatic","children":[{"id":3049,"name":"pancreatic_3049","title":"CXCR2 signaling in pancreatic cancer induces a tumor supporting inflammatory phenotype of the cancer-associated fibroblasts","presenterFirst":"Mohammad","presenterLast":"Awaji","keywords":"Chemokines;Cancer associated fibroblasts","target":"CXCR2","tumor":"pancreatic","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":3534,"name":"pancreatic_3534","title":"The TLR7/8 agonist R848 induces antitumor responses and attenuates cachexia in a murine model of pancreatic ductal adenocarcinoma","presenterFirst":"Katherine","presenterLast":"Michaelis","keywords":"Cachexia;Immunotherapy;TLR7;Mouse models","target":"TLR7/8","tumor":"pancreatic","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5613,"name":"pancreatic_5613","title":"Epigenetic modulation of the tumor microenvironment enhances immune checkpoint efficacy in a murine model of pancreatic cancer","presenterFirst":"Brian","presenterLast":"Christmas","keywords":"Pancreatic cancer;Epigenetics;Checkpoint;Tumor microenvironment","target":"HDAC","tumor":"pancreatic","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":7868,"name":"pancreatic_7868","title":"Cxcl-12-cxcr4 inhibition enhances immune response in pancreatic ductal adenocarcinoma","presenterFirst":"Bharti","presenterLast":"Garg","keywords":"T cell;Stroma;Cancer;Immune response","target":"CXCL12","tumor":"pancreatic","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":9276,"name":"pancreatic_9276","title":"A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer","presenterFirst":"Dung","presenterLast":"Le","keywords":"Chemokine receptor;immunosuppression;CCR2/5;tumor-associated myeloid and T cells","target":"CCR2/5","tumor":"pancreatic","sage":"target-tumor","pharma":"academia","combo":"yes","model":"clinical"},{"id":10771,"name":"pancreatic_10771","title":"Promoting an anti-tumor immune environment with a novel, exquisitely selective CSF1R inhibitor","presenterFirst":"Joseph","presenterLast":"Marszalek","keywords":"Macrophages;Drug discovery;CSF1R","target":"CSF1-R","tumor":"pancreatic","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"prostate","name":"prostate","presenterLast":"prostate","children":[{"id":3241,"name":"prostate_3241","title":"Preclinical evaluation of the multi tyrosine kinase inhibitor TAS-115 in genetically engineered mouse models of prostate cancer","presenterFirst":"Hirotsugu","presenterLast":"Uemura","keywords":"Kinase inhibitors;Targeted therapy;Prostate cancer;Preclinical testing","target":"CSF1-R","tumor":"prostate","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5044,"name":"prostate_5044","title":"The CX3CR1-Fractalkine axis drives both circulating prostate cancer cells and macrophages to the bone metastatic microenvironment","presenterFirst":"Ramanpreet","presenterLast":"Kaur","keywords":"Prostate cancer;Microenvironment;Chemokine receptor;Macrophages","target":"CX3CR1","tumor":"prostate","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":5296,"name":"prostate_5296","title":"Obesity and prostate cancer progression: Role of the chemokine CXCL12","presenterFirst":"Songyeon","presenterLast":"Ahn","keywords":"Obesity;Prostate cancer;CXCL12;CXCR4/CXCR7","target":"CXCR4","tumor":"prostate","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"renal","name":"renal","presenterLast":"renal","children":[{"id":3699,"name":"renal_3699","title":"Novel, heterocyclic small molecule inhibitors of PD-1 and PD-L1 pathway","presenterFirst":"Sivanandhan","presenterLast":"Dhanalakshmi","keywords":"Immunomodulation;Small molecule inhibitor","target":"PD1/L1","tumor":"renal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"sarcoma","name":"sarcoma","presenterLast":"sarcoma","children":[{"id":6334,"name":"sarcoma_6334","title":"Dual E-selectin and CXCR4 inhibition reduces tumor growth and metastatic progression in an orthotopic model of osteosarcoma","presenterFirst":"Wei","presenterLast":"Ju","keywords":"E-selectin;CXCR4;Osteosarcoma","target":"Eselectin_CXCR4","tumor":"sarcoma","sage":"target-tumor","pharma":"pharma","combo":"No","model":"preclinical xeno"}]}]}
